Document Detail


Pharmacogenetics of anti-inflammatory treatment in children with asthma: rationale and design of the PACMAN cohort.
MedLine Citation:
PMID:  19663678     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: To investigate the effects of genetic variation on treatment response to asthma medication in children and to identify (profiles of) SNPs that characterize response phenotypes. MATERIAL & METHODS: The Pharmacogenetics of Asthma medication in Children: Medication with Anti-inflammatory effects (PACMAN) study was initiated in April 2009 as an observational retrospective pharmacy-based study, including at least 1000 children with asthma medication (aged 4-12 years). Data on respiratory symptoms and medication use behavior will be collected using a questionnaire; complete medication histories will be extracted from the pharmacy information system; additional health information will be requested from the general practitioner; quality of inhalation technique and lung function measurements will be performed and saliva samples for DNA extraction and genotyping will be collected. Two groups of patients will be defined based on questionnaire data and lung function measurements: responders and nonresponders to anti-inflammatory asthma treatment. These two groups will be compared with respect to genetic variation. Corrections will be made for potential confounding factors. RESULTS: The main study end point is treatment response, including asthma control, medication use and exhaled nitric oxide as a measure of airway inflammation. Whilst our focus is on genetic factors, this study allows us to also investigate other treatment response determinants, such as inhalation technique and therapy adherence. CONCLUSION: Results from the PACMAN study could eventually lead to a more individualized therapy approach. PACMAN will focus on pharmacogenetics of asthma medication in children, while knowledge will be gained of relevant interest to the treatment of the asthma population at large.
Authors:
Ellen S Koster; Jan Am Raaijmakers; Gerard H Koppelman; Dirkje S Postma; Cornelis K van der Ent; Leo Koenderman; Madelon Bracke; Anke Hilse Maitland-van der Zee
Related Documents :
16845978 - Sinusitis: allergies, antibiotics, aspirin, asthma.
18958 - Newer medications to aid treatment of asthma.
15460688 - Asistastm telematic assistance for chronic asthma.
490148 - Panic-fear in asthma. symptomatology as an index of signal anxiety and personality as a...
2224678 - Medical education for alcohol and other drug abuse in the united states.
16781108 - Nature and frequency of exchanges on medications during primary care encounters.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pharmacogenomics     Volume:  10     ISSN:  1744-8042     ISO Abbreviation:  Pharmacogenomics     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-08-11     Completed Date:  2010-02-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897350     Medline TA:  Pharmacogenomics     Country:  England    
Other Details:
Languages:  eng     Pagination:  1351-61     Citation Subset:  IM    
Affiliation:
Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, 3508 TB Utrecht, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Adrenal Cortex Hormones / administration & dosage,  pharmacokinetics,  therapeutic use
Anti-Asthmatic Agents / administration & dosage,  pharmacokinetics,  therapeutic use*
Anti-Inflammatory Agents / administration & dosage,  pharmacokinetics,  therapeutic use
Asthma / drug therapy*,  genetics*
Child
Child, Preschool
Clinical Trials as Topic
Cohort Studies
Cross-Sectional Studies
Humans
Leukotriene Antagonists / administration & dosage,  pharmacokinetics,  therapeutic use
Netherlands
Pharmacogenetics / methods*
Pilot Projects
Polymorphism, Genetic*
Questionnaires
Respiratory Function Tests
Retrospective Studies
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Anti-Asthmatic Agents; 0/Anti-Inflammatory Agents; 0/Leukotriene Antagonists

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacogenetics of testosterone replacement therapy.
Next Document:  Placental expression of proteases and their inhibitors in patients with HELLP syndrome.